In April, the Food and Drug Administration will restrict who can make and sell popular weight-loss medications known as GLP-1s. In 2022, weight-loss drugs like Ozempic, Wegovy and others experienced a surge in popularity. In order to meet skyrocketing demand, the FDA gave permission to compounding pharmacies to make non-brand name copies of those drugs. The FDA now says the manufacturers of brand-name drugs have caught up, and starting April 22, special permission for compounding pharmacies will be revoked. Full story: https://www.ktvu.com/news/fda-restrict-some-makers-weight-loss-drugs-starting-next-month